Patent 11246862 was granted and assigned to Mankind Pharma Ltd on February, 2022 by the United States Patent and Trademark Office.
The present invention relates to a novel process for the preparation of lifitegrast of Formula I. The present invention further provides a novel process for the purification of lifitegrast of Formula I.